68Ga-OPS202 for Imaging GEP-NETs

Phase 2, open-label, single-arm trial of satoreotide in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Ipsen. Primary endpoints: Number of Participants Reported With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Drug Reactions (ADRs) and Number of Participants With Clinical Significant Abnormalities in Laboratory Parameters, Vital Signs, Cardiac Safety, Physical Examination, and Required Concomitant Medication. Started Jun 2014; status: completed.